Therapeutic outcome for the treatment of
glioma was often limited due to the non-targeted nature of drugs and the physiological barriers, including the blood-brain barrier (BBB) and the blood-
brain tumor barrier (BBTB). An ideal
glioma-targeted delivery system must be sufficiently potent to cross the BBB and BBTB and then target
glioma cells with adequate optimized physiochemical properties and biocompatibility. However, it is an enormous challenge to the researchers to engineer the above-mentioned features into a single nanocarrier particle. New frontiers in nanomedicine are advancing the research of new
biomaterials. In this study, we demonstrate a strategy for
glioma targeting by encapsulating
vincristine sulfate (VCR) into a naturally available
apoferritin nanocage-based drug delivery system with the modification of GKRK
peptide ligand (GKRK-APO).
Apoferritin (APO), an endogenous nanosize spherical
protein, can specifically bind to brain endothelial cells and
glioma cells via interacting with the
transferrin receptor 1 (TfR1). GKRK is a
peptide ligand of
heparan sulfate proteoglycan (
HSPG) over-expressed on angiogenesis and
glioma, presenting excellent
glioma-homing property. By combining the dual-targeting delivery effect of GKRK
peptide and parent APO, GKRK-APO displayed higher
glioma localization than that of parent APO. After loading with VCR, GKRK-APO showed the most favorable antiglioma effect in vitro and in vivo. These results demonstrated that GKRK-APO is an important potential drug delivery system for
glioma-targeted
therapy.